Article Versions Notes

Yin W, Xu T, Altai M, Oroujeni M, Zhang J, Vorobyeva A, Vorontsova O, Vtorushin SV, Tolmachev V, Gräslund T, et al. The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy. Pharmaceutics. 2021; 13(11):1974. https://doi.org/10.3390/pharmaceutics13111974

Yin, Wen, Tianqi Xu, Mohamed Altai, Maryam Oroujeni, Jie Zhang, Anzhelika Vorobyeva, Olga Vorontsova, Sergey V. Vtorushin, Vladimir Tolmachev, Torbjörn Gräslund, and et al. 2021. "The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy" Pharmaceutics 13, no. 11: 1974. https://doi.org/10.3390/pharmaceutics13111974

Yin, W., Xu, T., Altai, M., Oroujeni, M., Zhang, J., Vorobyeva, A., Vorontsova, O., Vtorushin, S. V., Tolmachev, V., Gräslund, T., & Orlova, A. (2021). The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy. Pharmaceutics, 13(11), 1974. https://doi.org/10.3390/pharmaceutics13111974